APO RESEARCH · REPORT
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service
Selected research
Industry Research
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Research Report 2026
Market perspective
The global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service include SGS, Quanticate, Mercodia, Creative Biolabs, Allucent, IRBM, Pacific BioLabs, Altasciences and Celerion, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market by Company
SGS
Quanticate
Mercodia
Creative Biolabs
Allucent
IRBM
Pacific BioLabs
Altasciences
Celerion
Labcorp
Oncodesign Services
Drug Development Solutions
CD BioSciences
Creative-Bioarray
Biotrial
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Type
In Vivo PK and PD Service
PK and PD modelling
DMPK Analysis
Ligand-Binding
Others
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Application
Pharmaceutical Company
Research Institute
Others
Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- In Vivo PK and PD Service
- PK and PD modelling
- DMPK Analysis
- Ligand-Binding
- Others
Applications
- Pharmaceutical Company
- Research Institute
- Others
Companies covered
- SGS
- Quanticate
- Mercodia
- Creative Biolabs
- Allucent
- IRBM
- Pacific BioLabs
- Altasciences
- Celerion
- Labcorp
- Oncodesign Services
- Drug Development Solutions
- CD BioSciences
- Creative-Bioarray
- Biotrial
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 In Vivo PK and PD Service
- 2.2.3 PK and PD modelling
- 2.2.4 DMPK Analysis
- 2.2.5 Ligand-Binding
- 2.2.6 Others
- 2.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Pharmaceutical Company
- 2.3.3 Research Institute
- 2.3.4 Others
- 2.4 Assumptions and Limitations
3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Breakdown Data by Type
- 3.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Historic Market Size by Type (2021-2026)
- 3.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Forecasted Market Size by Type (2027-2032)
4 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Breakdown Data by Application
- 4.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Historic Market Size by Application (2021-2026)
- 4.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Perspective (2021-2032)
- 5.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Growth Trends by Region
- 5.2.1 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Historic Market Size by Region (2021-2026)
- 5.2.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Forecasted Market Size by Region (2027-2032)
- 5.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Dynamics
- 5.3.1 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Trends
- 5.3.2 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Drivers
- 5.3.3 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Challenges
- 5.3.4 Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players by Revenue
- 6.1.1 Global Top Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players by Revenue (2021-2026)
- 6.1.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Head Office and Area Served
- 6.4 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Players, Product Type & Application
- 6.5 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Manufacturers Established Date
- 6.6 Global Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (2021-2032)
- 7.2 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2021-2026)
- 7.4 North America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (2021-2032)
- 8.2 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2021-2026)
- 8.4 Europe Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (2021-2032)
- 9.2 Asia-Pacific Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (2021-2032)
- 10.2 South America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2021-2026)
- 10.4 South America Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size (2021-2032)
- 11.2 Middle East & Africa Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 SGS
- 12.1.1 SGS Company Information
- 12.1.2 SGS Business Overview
- 12.1.3 SGS Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.1.4 SGS Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.1.5 SGS Recent Developments
- 12.2 Quanticate
- 12.2.1 Quanticate Company Information
- 12.2.2 Quanticate Business Overview
- 12.2.3 Quanticate Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.2.4 Quanticate Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.2.5 Quanticate Recent Developments
- 12.3 Mercodia
- 12.3.1 Mercodia Company Information
- 12.3.2 Mercodia Business Overview
- 12.3.3 Mercodia Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.3.4 Mercodia Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.3.5 Mercodia Recent Developments
- 12.4 Creative Biolabs
- 12.4.1 Creative Biolabs Company Information
- 12.4.2 Creative Biolabs Business Overview
- 12.4.3 Creative Biolabs Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.4.4 Creative Biolabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.4.5 Creative Biolabs Recent Developments
- 12.5 Allucent
- 12.5.1 Allucent Company Information
- 12.5.2 Allucent Business Overview
- 12.5.3 Allucent Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.5.4 Allucent Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.5.5 Allucent Recent Developments
- 12.6 IRBM
- 12.6.1 IRBM Company Information
- 12.6.2 IRBM Business Overview
- 12.6.3 IRBM Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.6.4 IRBM Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.6.5 IRBM Recent Developments
- 12.7 Pacific BioLabs
- 12.7.1 Pacific BioLabs Company Information
- 12.7.2 Pacific BioLabs Business Overview
- 12.7.3 Pacific BioLabs Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.7.4 Pacific BioLabs Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.7.5 Pacific BioLabs Recent Developments
- 12.8 Altasciences
- 12.8.1 Altasciences Company Information
- 12.8.2 Altasciences Business Overview
- 12.8.3 Altasciences Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.8.4 Altasciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.8.5 Altasciences Recent Developments
- 12.9 Celerion
- 12.9.1 Celerion Company Information
- 12.9.2 Celerion Business Overview
- 12.9.3 Celerion Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.9.4 Celerion Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.9.5 Celerion Recent Developments
- 12.10 Labcorp
- 12.10.1 Labcorp Company Information
- 12.10.2 Labcorp Business Overview
- 12.10.3 Labcorp Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.10.4 Labcorp Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.10.5 Labcorp Recent Developments
- 12.11 Oncodesign Services
- 12.11.1 Oncodesign Services Company Information
- 12.11.2 Oncodesign Services Business Overview
- 12.11.3 Oncodesign Services Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.11.4 Oncodesign Services Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.11.5 Oncodesign Services Recent Developments
- 12.12 Drug Development Solutions
- 12.12.1 Drug Development Solutions Company Information
- 12.12.2 Drug Development Solutions Business Overview
- 12.12.3 Drug Development Solutions Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.12.4 Drug Development Solutions Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.12.5 Drug Development Solutions Recent Developments
- 12.13 CD BioSciences
- 12.13.1 CD BioSciences Company Information
- 12.13.2 CD BioSciences Business Overview
- 12.13.3 CD BioSciences Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.13.4 CD BioSciences Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.13.5 CD BioSciences Recent Developments
- 12.14 Creative-Bioarray
- 12.14.1 Creative-Bioarray Company Information
- 12.14.2 Creative-Bioarray Business Overview
- 12.14.3 Creative-Bioarray Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.14.4 Creative-Bioarray Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.14.5 Creative-Bioarray Recent Developments
- 12.15 Biotrial
- 12.15.1 Biotrial Company Information
- 12.15.2 Biotrial Business Overview
- 12.15.3 Biotrial Revenue in Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Business (2021-2026)
- 12.15.4 Biotrial Pharmacokinetics (PK) and pharmacodynamics (PD) Analysis Service Product Portfolio
- 12.15.5 Biotrial Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst